{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,15]],"date-time":"2026-11-15T03:37:17Z","timestamp":1794713837671,"version":"4.9.1"},"reference-count":45,"publisher":"BMJ","issue":"14","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Heart"],"accepted":{"date-parts":[[2020,3,13]]},"published-print":{"date-parts":[[2020,7]]},"abstract":"<jats:p>Acute idiopathic or so-called viral pericarditis is a frequent and usually benign disease, although recurrences are frequent. Data strongly suggest the presence of underlying autoinflammatory and\/or autoimmune disorders. It has been reported that there is an inflammatory response of the innate immune system typical of \u2018autoinflammatory diseases\u2019, predominantly mediated by interleukin-1 (IL-1). This may result from the activation of the inflammasome by a cardiotropic virus or a non-specific agent. The inflammatory response of the adaptive immune system, typical of \u2018autoimmune diseases\u2019\u2014mainly mediated by autoantibodies or autoreactive T lymphocytes\u2014seems also involved as anti-heart or anti-intercalated disk autoantibodies were associated with a higher number of recurrences and hospitalisations. Current guidelines recommend that aspirin\/non-steroidal anti-inflammatory drugs for a few weeks should be associated to colchicine for 6 months in recurrent pericarditis. In refractory cases, low-dose corticosteroids or immunosuppressive drugs have been proposed with limited efficacy. Growing evidences suggest a place of IL-1 receptor antagonists in the treatment of recurrent pericarditis. Many retrospective studies, one recent randomised placebo-controlled study and data of a real-life large international registry showed the good efficacy of anakinra with a good safety profile. Other IL-1 receptor antagonists showed promising results (canakinumab, rilonacept). However, IL-1 receptor antagonists\u2019 position in the treatment algorithm of recurrent pericarditis needs further evaluation in larger prospective clinical trials to replicate initial findings as well as to assess safety, cost-effectiveness and long-term efficacy.<\/jats:p>","DOI":"10.1136\/heartjnl-2019-316481","type":"journal-article","created":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T17:15:24Z","timestamp":1585761324000},"page":"1046-1051","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":32,"title":["Acute recurrent pericarditis: from pathophysiology towards new treatment strategy"],"prefix":"10.1136","volume":"106","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6727-4992","authenticated-orcid":false,"given":"Patrice","family":"Cacoub","sequence":"first","affiliation":[{"name":"Department of Internal Medicine and Clinial Immunology, AP-HP, Groupe Hospitalier Piti\u00e9-Salp\u00eatri\u00e8re, Department of Internal Medicine, Paris, France"},{"name":"D\u00e9partement Hospitalo-Universitaire I2, Sorbonne Universit\u00e9, UPMC Univ Paris 06, Paris, France"},{"name":"CNRS, UMR 7211, Paris, France"},{"name":"INSERM, UMR_S 959, F-75013, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cindy","family":"Marques","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine and Clinial Immunology, AP-HP, Groupe Hospitalier Piti\u00e9-Salp\u00eatri\u00e8re, Department of Internal Medicine, Paris, France"},{"name":"D\u00e9partement Hospitalo-Universitaire I2, Sorbonne Universit\u00e9, UPMC Univ Paris 06, Paris, France"},{"name":"CNRS, UMR 7211, Paris, France"},{"name":"INSERM, UMR_S 959, F-75013, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2020,4,1]]},"reference":[{"key":"2025092101551216000_106.14.1046.1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2003.09.055"},{"key":"2025092101551216000_106.14.1046.2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehv318"},{"key":"2025092101551216000_106.14.1046.3","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1016\/S0140-6736(14)60113-6","article-title":"Colchicine for treatment of acute or recurrent pericarditis","volume":"383","author":"Cacoub","year":"2014","journal-title":"Lancet"},{"key":"2025092101551216000_106.14.1046.4","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1016\/j.revmed.2011.02.018","article-title":"[What\u2019s new in recurrent pericarditis in 2011?]","volume":"32","author":"Geri","year":"2011","journal-title":"Rev Med Interne"},{"key":"2025092101551216000_106.14.1046.5","doi-asserted-by":"publisher","DOI":"10.1007\/s10741-013-9382-y"},{"key":"2025092101551216000_106.14.1046.6","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.106.662114"},{"key":"2025092101551216000_106.14.1046.7","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2015.12763"},{"key":"2025092101551216000_106.14.1046.8","first-page":"241","article-title":"[Chronic constrictive pericarditis. A retrospective study of a series of 84 patients]","volume":"87","author":"Nataf","year":"1994","journal-title":"Arch Mal Coeur Vaiss"},{"key":"2025092101551216000_106.14.1046.9","doi-asserted-by":"publisher","DOI":"10.1016\/1010-7940(93)90213-U"},{"key":"2025092101551216000_106.14.1046.10","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2012.07.023"},{"key":"2025092101551216000_106.14.1046.11","doi-asserted-by":"publisher","DOI":"10.1007\/PL00001993"},{"key":"2025092101551216000_106.14.1046.12","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-202708"},{"key":"2025092101551216000_106.14.1046.13","doi-asserted-by":"publisher","DOI":"10.1016\/S0092-8674(00)80539-5"},{"key":"2025092101551216000_106.14.1046.14","first-page":"139","article-title":"Recurrent pericarditis as the initial manifestation of familial Mediterranean fever","volume":"14","author":"Okutur","year":"2008","journal-title":"Med Sci Monit"},{"key":"2025092101551216000_106.14.1046.15","doi-asserted-by":"publisher","DOI":"10.1191\/0961203305lu2197oa"},{"key":"2025092101551216000_106.14.1046.16","doi-asserted-by":"publisher","DOI":"10.1038\/nature06664"},{"key":"2025092101551216000_106.14.1046.17","doi-asserted-by":"publisher","DOI":"10.1136\/hrt.2009.187138"},{"key":"2025092101551216000_106.14.1046.18","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2006.01.086"},{"key":"2025092101551216000_106.14.1046.19","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.111.018580"},{"key":"2025092101551216000_106.14.1046.20","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2007.04.047"},{"key":"2025092101551216000_106.14.1046.21","doi-asserted-by":"publisher","DOI":"10.1136\/hrt.2003.026120"},{"key":"2025092101551216000_106.14.1046.22","doi-asserted-by":"publisher","DOI":"10.1007\/s10741-012-9328-9"},{"key":"2025092101551216000_106.14.1046.23","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.105.542738"},{"key":"2025092101551216000_106.14.1046.24","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1208536"},{"key":"2025092101551216000_106.14.1046.25","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.165.17.1987"},{"key":"2025092101551216000_106.14.1046.26","first-page":"290","article-title":"Colchicine for Recurrent Pericarditis (CORP) a randomized trial","volume":"9","author":"Imazio","year":"2014","journal-title":"Ann Intern Med"},{"key":"2025092101551216000_106.14.1046.27","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)62709-9"},{"key":"2025092101551216000_106.14.1046.28","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehi197"},{"key":"2025092101551216000_106.14.1046.29","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.107.761064"},{"key":"2025092101551216000_106.14.1046.30","article-title":"Steroids and immunosuppressive agents in idiopathic refractory recurrent pericarditis: a single-center experience","volume":"38S","author":"Peiffer-Smadja","year":"2017","journal-title":"Rev Med Interne"},{"key":"2025092101551216000_106.14.1046.31","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/j.amjcard.2015.12.012","article-title":"Usefulness of novel immunotherapeutic strategies for idiopathic recurrent pericarditis","volume":"117","author":"Lotan","year":"2016","journal-title":"Am J Cardiol"},{"key":"2025092101551216000_106.14.1046.32","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2011.01.027"},{"key":"2025092101551216000_106.14.1046.33","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2013.06.036"},{"key":"2025092101551216000_106.14.1046.34","doi-asserted-by":"crossref","first-page":"263","DOI":"10.2459\/JCM.0000000000000260","article-title":"Intravenous human immunoglobulins for refractory recurrent pericarditis: a systematic review of all published cases","volume":"17","author":"Imazio","year":"2016","journal-title":"J Cardiovasc Med"},{"key":"2025092101551216000_106.14.1046.35","doi-asserted-by":"publisher","DOI":"10.1002\/art.24174"},{"key":"2025092101551216000_106.14.1046.36","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2014.01.065"},{"key":"2025092101551216000_106.14.1046.37","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2014-205990"},{"key":"2025092101551216000_106.14.1046.38","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1016\/j.amjcard.2015.07.047","article-title":"Effectiveness and safety of anakinra for management of refractory pericarditis","volume":"116","author":"Jain","year":"2015","journal-title":"Am J Cardiol"},{"key":"2025092101551216000_106.14.1046.39","unstructured":"Betancourt B , Ombrello A , Subedi A , et al . Recurrent pericarditis: a challenge in autoinflammatory disease clinic and the role of anakinra. Arthritis Rheumatol 2018;70."},{"key":"2025092101551216000_106.14.1046.40","doi-asserted-by":"crossref","first-page":"256","DOI":"10.2459\/JCM.0000000000000266","article-title":"Anakinra: an emerging option for refractory idiopathic recurrent pericarditis: a systematic review of published evidence","volume":"17","author":"Lazaros","year":"2016","journal-title":"J Cardiovasc Med"},{"key":"2025092101551216000_106.14.1046.41","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2016.15826"},{"key":"2025092101551216000_106.14.1046.42","article-title":"Anakinra for corticosteroid-dependent and colchicine-resistant pericarditis: the IRAP (International Registry of Anakinra for Pericarditis) study","volume":"2019","author":"Imazio","year":"2019","journal-title":"Eur J Prev Cardiol"},{"key":"2025092101551216000_106.14.1046.43","unstructured":"Klein A , Lin D , Cremer P , et al . Abstract 12851: efficacy and safety of rilonacept in recurrent pericarditis: a multicenter phase 2 clinical trial. Circulation 2019;140."},{"key":"2025092101551216000_106.14.1046.44","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.111.026153"},{"key":"2025092101551216000_106.14.1046.45","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2014.11026"}],"container-title":["Heart"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/heartjnl-2019-316481","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T08:55:20Z","timestamp":1758444920000},"score":1,"resource":{"primary":{"URL":"https:\/\/heart.bmj.com\/lookup\/doi\/10.1136\/heartjnl-2019-316481"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,1]]},"references-count":45,"journal-issue":{"issue":"14","published-online":{"date-parts":[[2020,6,25]]},"published-print":{"date-parts":[[2020,7]]}},"alternative-id":["10.1136\/heartjnl-2019-316481"],"URL":"https:\/\/doi.org\/10.1136\/heartjnl-2019-316481","relation":{},"ISSN":["1355-6037","1468-201X"],"issn-type":[{"value":"1355-6037","type":"print"},{"value":"1468-201X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,1]]}}}